Skip to main content
. 2015 Jun 8;16(1):68. doi: 10.1186/s12931-015-0227-1

Table 4.

V0162 pharmacokinetic parameters for different dose cohorts in healthy volunteers and in COPD patients

V0162 dose tmax (h) Cmax (pg/mL) AUC0-t (h.pg/mL) t1/2 (h)
Healthy volunteers Median Mean SD Mean SD Mean SD
10 μg nc nc nc nc nc nc nc
50 μg 0.08 40 14 555 790 26 13
100 μg 0.08 108 41 1872 1981 19 0.69
200 μg 0.08 149 33 4578 2633 28 11
400 μg 0.08 431 268 6529 3774 23 8.08
800 μg 0.08 1030 311 17670 13735 19 4.88
1200 μg 0.08 2180 2030 17646 12297 20 11
1600 μg 0.08 2270 618 32692 13447 36 15
2000 μg 0.08 2970 1800 41192 37151 19 3.55
2400 μg 0.10 2840 1040 26820 16211 17 3.40
100 μg + charcoal 0.08 98 65 560 250 21 3.99
200 μg + charcoal 0.08 81 28.8 1483 411 32 13
400 μg + charcoal 0.08 359 216 3541 1871 27 8.32
2400 μg + ipratropium/fenoterol 0.11 2600 824 31200 9941 19 4.17
COPD patients
1600 μg 0.08 1040 577 13872.8 6461 nc nc

nc not calculated (more than 50 % of plasma values were below the lower limit of quantification (5.00 pg/mL)